Joslin Researchers Conduct First Trial Directly Comparing Drugs for Diabetic Macular Edema and Find All are Effective

Joslin Researchers Conduct First Trial. Trial provides more definitive data to guide clinicians

BOSTON   – In the first clinical trial directly comparing three drugs most commonly used to treat diabetic macular edema, researchers found all were effective in improving vision and preventing vision loss. However, one drug, aflibercept, provided greater improvement for people with more severe vision loss when treatment was initiated. The trial was conducted by the National Eye Institute Diabetic Retinopathy Clinical Research Network (DRCR.net) including researchers from Joslin Diabetes Center. The results appeared in the February online edition of the New England Journal of Medicine.
Diabetes is a significant risk factor for developing eye diseases. The most common diabetic eye disease and a leading cause of blindness is diabetic retinopathy, which is caused by elevated blood sugar levels damaging the blood vessels of the retina and affects approximately 7.7 million Americans. About 750,000 Americans with diabetic retinopathy have diabetic macular edema (DME) in which fluid leaks into the macula, the area of the retina used when looking straight ahead. The fluid causes the macula to swell, blurring vision. “DME is the leading cause of moderate vision loss in working-age adults with diabetes……
Read more: http://www.healthcanal.com/metabolic-problems/diabetes/60826-joslin-researchers-conduct-first-trial-directly-comparing-drugs-for-diabetic-macular-edema-and-find-all-are-effective.html
 
Source: Healthcanal
On